Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

Leukemia·2025
Same author

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Leukemia·2025
Same author

Liver transplantation in well-selected patients with unresectable colorectal liver metastases.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2025
Same author

Are real world data real world data?

Leukemia·2025
Same author

Combined heterozygosity for the highly unstable variant hemoglobin Taybe, and α-thalassemia as a rare cause of hemolytic anemia.

Annals of hematology·2025
Same author

Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia.

Leukemia·2025

Related Experiment Video

Updated: Jul 13, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Chronic myeloid leukaemia.

Rüdiger Hehlmann1, Andreas Hochhaus, Michele Baccarani

  • 1III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany. Ruediger.Hehlmann@med3.ma.uni-heidelberg.de

Lancet (London, England)
|July 31, 2007
PubMed
Summary

Chronic myeloid leukaemia (CML) is a model cancer due to its clear cause and targeted therapy. Imatinib revolutionized CML treatment, with high remission rates and ongoing research for new therapies.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Experiment Videos

Last Updated: Jul 13, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Area of Science:

  • Oncology
  • Hematology
  • Pharmacogenomics

Background:

  • Chronic myeloid leukaemia (CML) is a neoplastic disease with a well-understood pathophysiology.
  • Its genetic basis (BCR-ABL fusion gene) enabled the development of targeted therapies.
  • CML serves as a paradigm for genotype-driven cancer treatment.

Purpose of the Study:

  • To review the current management of chronic-phase CML.
  • To provide guidance on monitoring disease status in CML patients.
  • To highlight the impact of targeted therapy on CML outcomes.

Main Methods:

  • Literature review of CML pathophysiology, diagnosis, and treatment.
  • Analysis of treatment guidelines and clinical trial outcomes.
  • Discussion of monitoring strategies for achieving complete cytogenetic remission.

Main Results:

  • Imatinib, a BCR-ABL tyrosine kinase inhibitor, is the standard first-line treatment for chronic-phase CML.
  • High rates of complete cytogenetic remission (up to 87%) are achievable with imatinib.
  • Alternative treatments include interferon alfa, stem-cell transplantation, dose escalation, or novel agents upon treatment failure.

Conclusions:

  • Imatinib has transformed CML management, offering high efficacy and improved patient outcomes.
  • Close monitoring is crucial for assessing treatment response and managing CML.
  • Ongoing research explores new drugs and combination therapies to further enhance CML treatment.